14 results on '"Migliorini, Denis"'
Search Results
2. Glycan-directed CAR-T cells.
- Author
-
Steentoft, Catharina, Migliorini, Denis, King, Tiffany R, Mandel, Ulla, June, Carl H, and Posey, Avery D
- Subjects
- *
GLYCANS , *CANCER immunotherapy , *CHIMERIC antigen receptors , *LYMPHOBLASTIC leukemia , *T cell receptors ,BONE marrow cancer - Abstract
Cancer immunotherapy is rapidly advancing in the treatment of a variety of hematopoietic cancers, including pediatric acute lymphoblastic leukemia and diffuse large B cell lymphoma, with chimeric antigen receptor (CAR)-T cells. CARs are genetically encoded artificial T cell receptors that combine the antigen specificity of an antibody with the machinery of T cell activation. However, implementation of CAR technology in the treatment of solid tumors has been progressing much slower. Solid tumors are characterized by a number of challenges that need to be overcome, including cellular heterogeneity, immunosuppressive tumor microenvironment (TME), and, in particular, few known cancer-specific targets. Post-translational modifications that differentially occur in malignant cells generate valid cell surface, cancer-specific targets for CAR-T cells. We previously demonstrated that CAR-T cells targeting an aberrant O-glycosylation of MUC1, a common cancer marker associated with changes in cell adhesion, tumor growth and poor prognosis, could control malignant growth in mouse models. Here, we discuss the field of glycan-directed CAR-T cells and review the different classes of antibodies specific for glycan-targeting, including the generation of high affinity O-glycopeptide antibodies. Finally, we discuss historic and recently investigated glycan targets for CAR-T cells and provide our perspective on how targeting the tumor glycoproteome and/or glycome will improve CAR-T immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
- Author
-
Genoud, Vassilis, Migliorini, Denis, Di Bartolomeo, Sabrina, and Segatto, Marco
- Subjects
- *
GLIOBLASTOMA multiforme ,CENTRAL nervous system tumors - Abstract
Glioblastoma is the most frequent primary neoplasm of the central nervous system and still suffers from very poor therapeutic impact. No clear improvements over current standard of care have been made in the last decade. For other cancers, but also for brain metastasis, which harbors a very distinct biology from glioblastoma, immunotherapy has already proven its efficacy. Efforts have been pursued to allow glioblastoma patients to benefit from these new approaches, but the road is still long for broad application. Here, we aim to review key glioblastoma immune related characteristics, current immunotherapeutic strategies being explored, their potential caveats, and future directions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.
- Author
-
Parker, Kevin R., Migliorini, Denis, Perkey, Eric, Yost, Kathryn E., Bhaduri, Aparna, Bagga, Puneet, Haris, Mohammad, Wilson, Neil E., Liu, Fang, Gabunia, Khatuna, Scholler, John, Montine, Thomas J., Bhoj, Vijay G., Reddy, Ravinder, Mohan, Suyash, Maillard, Ivan, Kriegstein, Arnold R., June, Carl H., Chang, Howard Y., and Posey, Avery D.
- Subjects
- *
BLOOD-brain barrier , *NEUROTOXICOLOGY , *RNA sequencing , *CHIMERIC antigen receptors , *T cells , *CELL surface antigens , *CEREBRAL edema - Abstract
CD19-directed immunotherapies are clinically effective for treating B cell malignancies but also cause a high incidence of neurotoxicity. A subset of patients treated with chimeric antigen receptor (CAR) T cells or bispecific T cell engager (BiTE) antibodies display severe neurotoxicity, including fatal cerebral edema associated with T cell infiltration into the brain. Here, we report that mural cells, which surround the endothelium and are critical for blood-brain-barrier integrity, express CD19. We identify CD19 expression in brain mural cells using single-cell RNA sequencing data and confirm perivascular staining at the protein level. CD19 expression in the brain begins early in development alongside the emergence of mural cell lineages and persists throughout adulthood across brain regions. Mouse mural cells demonstrate lower levels of Cd19 expression, suggesting limitations in preclinical animal models of neurotoxicity. These data suggest an on-target mechanism for neurotoxicity in CD19-directed therapies and highlight the utility of human single-cell atlases for designing immunotherapies. • Single-cell RNA-seq reveals CD19 expression in human brain mural cells • Mural cells line blood vessels and maintain blood-brain barrier integrity • Brain mural cell CD19 expression is present across brain regions and human age • Targeting CD19+ mural cells may contribute to neurotoxicity of CAR-T therapy Single-cell RNA sequencing analysis shows that CD19, primarily considered as a B cell-specific surface antigen, is expressed in human brain mural cells that are critical for blood-brain-barrier integrity, suggesting that this cell population may contribute to the neurotoxicity of CD19-directed immunotherapy including CAR-T. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages.
- Author
-
Tankov, Stoyan, Petrovic, Marija, Lecoultre, Marc, Espinoza, Felipe, El-Harane, Nadia, Bes, Viviane, Chliate, Sylvie, Bedoya, Darel Martinez, Jordan, Olivier, Borchard, Gerrit, Migliorini, Denis, Dutoit, Valérie, and Walker, Paul R.
- Subjects
- *
EXTRACELLULAR vesicles , *T cells , *MACROPHAGES , *CANCER cells , *TUMOR microenvironment , *IMMUNE response , *CELL culture - Abstract
Background: Solid tumors such as glioblastoma (GBM) exhibit hypoxic zones that are associated with poor prognosis and immunosuppression through multiple cell intrinsic mechanisms. However, release of extracellular vesicles (EVs) has the potential to transmit molecular cargos between cells. If hypoxic cancer cells use EVs to suppress functions of macrophages under adequate oxygenation, this could be an important underlying mechanism contributing to the immunosuppressive and immunologically cold tumor microenvironment of tumors such as GBM. Methods: EVs were isolated by differential ultracentrifugation from GBM cell culture supernatant. EVs were thoroughly characterized by transmission and cryo-electron microscopy, nanoparticle tracking analysis (NTA), and EV marker expression by Western blot and fluorescent NTA. EV uptake by macrophage cells was observed using confocal microscopy. The transfer of miR-25/93 as an EV cargo to macrophages was confirmed by miRNA real-time qPCR. The impact of miR-25/93 on the polarization of recipient macrophages was shown by transcriptional analysis, cytokine secretion and functional assays using co-cultured T cells. Results: We show that indirect effects of hypoxia can have immunosuppressive consequences through an EV and microRNA dependent mechanism active in both murine and human tumor and immune cells. Hypoxia enhanced EV release from GBM cells and upregulated expression of miR-25/93 both in cells and in EV cargos. Hypoxic GBM-derived EVs were taken up by macrophages and the miR-25/93 cargo was transferred, leading to impaired cGAS-STING pathway activation revealed by reduced type I IFN expression and secretion by macrophages. The EV-treated macrophages downregulated expression of M1 polarization-associated genes Cxcl9, Cxcl10 and Il12b, and had reduced capacity to attract activated T cells and to reactivate them to release IFN-γ, key components of an efficacious anti-tumor immune response. Conclusions: Our findings suggest a mechanism by which immunosuppressive consequences of hypoxia mediated via miRNA-25/93 can be exported from hypoxic GBM cells to normoxic macrophages via EVs, thereby contributing to more widespread T-cell mediated immunosuppression in the tumor microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
- Author
-
Irving, Melita, Lanitis, Evripidis, Migliorini, Denis, Ivics, Zoltán, and Guedan, Sonia
- Subjects
- *
CD19 antigen , *B cell lymphoma , *TRANSPOSONS , *GENOME editing , *CURRENT good manufacturing practices , *CHIMERIC antigen receptors , *GENETIC engineering - Abstract
T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has shown tremendous promise for the treatment of B cell malignancies. The successful translation of CAR-T cell therapy to other tumor types, including solid tumors, is the next big challenge. As the field advances from second- to next-generation CAR-T cells comprising multiple genetic modifications, more sophisticated methods and tools to engineer T cells are being developed. Viral vectors, especially γ-retroviruses and lentiviruses, are traditionally used for CAR-T cell engineering due to their high transduction efficiency. However, limited genetic cargo, high costs of production under good manufacturing practice (GMP) conditions, and the high regulatory demands are obstacles for widespread clinical translation. To overcome these limitations, different nonviral approaches are being explored at a preclinical or clinical level, including transposon/transposase systems and mRNA electroporation and nonintegrating DNA nanovectors. Genome editing tools that allow efficient knockout of particular genes and/or site-directed integration of the CAR and/or other transgenes into the genome are also being evaluated for CAR-T cell engineering. In this review, we discuss the development of viral and nonviral vectors used to generate CAR-T cells, focusing on their advantages and limitations. We also discuss the lessons learned from clinical trials using the different genetic engineering tools, with special focus on safety and efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.
- Author
-
Dutoit, Valérie, Migliorini, Denis, Ranzanici, Giulia, Marinari, Eliana, Widmer, Valérie, Lobrinus, Johannes Alexander, Momjian, Shahan, Costello, Joseph, Walker, Paul R., Okada, Hideho, Weinschenk, Toni, Herold-Mende, Christel, and Dietrich, Pierre-Yves
- Subjects
- *
GLIOBLASTOMA multiforme treatment , *CANCER immunotherapy , *IMMUNE response - Abstract
Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising alternative strategy mostly developed in the context of glioblastoma. However, there is a need for implementing immunotherapy for grade II/III gliomas, as these are the most common CNS tumors in young adults with a high propensity for recurrence, making them lethal despite current treatments. We recently identified HLA-A2-restricted tumor-associated antigens by peptide elution from glioblastoma and formulated a multipeptide vaccine (IMA950) evaluated in phase I/II clinical trials with promising results. Here, we investigated expression of the IMA950 antigens in patients with grade II/III astrocytoma, oligodendroglioma or ependymoma, at the mRNA, protein and peptide levels. We report that the BCAN, CSPG4, IGF2BP3, PTPRZ1 and TNC proteins are significantly over-expressed at the mRNA (n = 159) and protein (n = 36) levels in grade II/III glioma patients as compared to non-tumor samples (IGF2BP3 being absent from oligodendroglioma). Most importantly, we detected spontaneous antigen-specific T cell responses to one or more of the IMA950 antigens in 100% and 71% of grade II and grade III patients, respectively (27 patients tested). These patients displayed T cell responses of better quality (higher frequency, broader epitope targeting) than patients with glioblastoma. Detection of spontaneous T cell responses to the IMA950 antigens shows that these antigens are relevant for tumor targeting, which will be best achieved by combination with CD4 epitopes such as the IDH1R132H peptide. Altogether, we provide the rationale for using a selective set of IMA950 peptides for vaccination of patients with grade II/III glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies.
- Author
-
Migliorini, Denis, Mach, Nicolas, Aguiar, Diego, Vernet, Rémi, Landis, Basile Nicolas, Becker, Minerva, McKee, Thomas, Dutoit, Valérie, and Dietrich, Pierre-Yves
- Subjects
- *
CHORDOMA , *CANCER immunotherapy , *CANCER relapse , *THERAPEUTICS - Abstract
Chordoma is a rare tumor of notochordal origin, currently principally treated by surgery and/or irradiation. Here, we describe the clinical outcome of 3 consecutive patients with metastatic and locally advanced chordoma, treated with different immunotherapeutic approaches. All patients presented fast growing tumors and failure of standard therapies. One was treated with a tumor-based vaccine, the 2 others with anti-PD1 antibodies, all with impressive clinical and radiological responses. We therefore propose that chordoma is an immunogenic tumor and thus that translational and clinical research is necessary to develop rationally designed immunotherapy approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis.
- Author
-
Muoio, Barbara, Albano, Domenico, Dondi, Francesco, Bertagna, Francesco, Garibotto, Valentina, Kunikowska, Jolanta, Piccardo, Arnoldo, Annunziata, Salvatore, Espeli, Vittoria, Migliorini, Denis, and Treglia, Giorgio
- Subjects
- *
POSITRON emission tomography , *GLIOMAS , *RADIOPHARMACEUTICALS , *MAGNETIC resonance imaging , *BRAIN tumors - Abstract
Background: Several studies proposed the use of positron emission tomography (PET) with Prostate Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in brain tumors. Our aim is to calculate the diagnostic accuracy of these methods in high-grade gliomas (HGG) with a bivariate meta-analysis. Methods: A comprehensive literature search of studies on the diagnostic accuracy of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in HGG was performed. Original articles evaluating these imaging methods both in the differential diagnosis between HGG and low-grade gliomas (LGG) and in the assessment of suspicious HGG recurrence were included. Pooled sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR-), and diagnostic odds ratio (DOR) including 95% confidence intervals (95% CI) were calculated. Statistical heterogeneity was also assessed using the I2 test. Results: The meta-analysis of six selected studies (157 patients) provided the following results about PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals in the diagnosis of HGG: sensitivity 98.2% (95% CI: 75.3–99.9%), specificity 91.2% (95% CI: 68.4–98.1%), LR+ 4.5 (95% CI: 2.2–9.3), LR− 0.07 (95% CI: 0.04–0.15), and DOR 70.1 (95% CI: 19.6–250.9). No significant statistical heterogeneity among the included studies was found (I2 = 0%). Conclusions: the quantitative data provided demonstrate the high diagnostic accuracy of PET/CT or PET/MRI with PSMA-targeting radiopharmaceuticals for HGG detection. However, more studies are needed to confirm the promising role of PSMA-targeted PET in this clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Cancer vaccines.
- Author
-
Schiller, John T., Lowy, Douglas R., Frazer, Ian H., Finn, Olivera J., Vilar, Eduardo, Lyerly, H. Kim, Gnjatic, Sacha, Zaidi, Neeha, Ott, Patrick A., Balachandran, Vinod P., Dietrich, Pierre-Yves, Migliorini, Denis, Vonderheide, Robert H., and Domchek, Susan M.
- Subjects
- *
CANCER vaccines , *VACCINE development , *COVID-19 pandemic , *CANCER prevention , *CARCINOGENESIS - Abstract
Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for their broad implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors.
- Author
-
Sostoa, Jana de, Dutoit, Valérie, and Migliorini, Denis
- Subjects
- *
BRAIN tumors , *CANCER , *INCURABLE diseases , *ONCOGENIC viruses , *TUMOR treatment - Abstract
Malignant brain tumors remain incurable diseases. Although much effort has been devoted to improving patient outcome, multiple factors such as the high tumor heterogeneity, the strong tumor-induced immunosuppressive microenvironment, and the low mutational burden make the treatment of these tumors especially challenging. Thus, novel therapeutic strategies are urgent. Oncolytic viruses (OVs) are biotherapeutics that have been selected or engineered to infect and selectively kill cancer cells. Increasingly, preclinical and clinical studies demonstrate the ability of OVs to recruit T cells and induce durable immune responses against both virus and tumor, transforming a "cold" tumor microenvironment into a "hot" environment. Besides promising clinical results as a monotherapy, OVs can be powerfully combined with other cancer therapies, helping to overcome critical barriers through the creation of synergistic effects in the fight against brain cancer. Although many questions remain to be answered to fully exploit the therapeutic potential of OVs, oncolytic virotherapy will clearly be part of future treatments for patients with malignant brain tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin.
- Author
-
Calvo Tardón, Marta, Marinari, Eliana, Migliorini, Denis, Bes, Viviane, Tankov, Stoyan, Charrier, Emily, McKee, Thomas A, Dutoit, Valérie, Dietrich, Pierre-Yves, Cosset, Erika, and Walker, Paul R
- Subjects
- *
GLIOBLASTOMA multiforme , *HYPOXEMIA , *BRAIN tumors , *METFORMIN , *OXYGEN consumption - Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor, characterized by a high degree of intertumoral heterogeneity. However, a common feature of the GBM microenvironment is hypoxia, which can promote radio- and chemotherapy resistance, immunosuppression, angiogenesis, and stemness. We experimentally defined common GBM adaptations to physiologically relevant oxygen gradients, and we assessed their modulation by the metabolic drug metformin. We directly exposed human GBM cell lines to hypoxia (1% O2) and to physioxia (5% O2). We then performed transcriptional profiling and compared our in vitro findings to predicted hypoxic areas in vivo using in silico analyses. We observed a heterogenous hypoxia response, but also a common gene signature that was induced by a physiologically relevant change in oxygenation from 5% O2 to 1% O2. In silico analyses showed that this hypoxia signature was highly correlated with a perinecrotic localization in GBM tumors, expression of certain glycolytic and immune-related genes, and poor prognosis of GBM patients. Metformin treatment of GBM cell lines under hypoxia and physioxia reduced viable cell number, oxygen consumption rate, and partially reversed the hypoxia gene signature, supporting further exploration of targeting tumor metabolism as a treatment component for hypoxic GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients.
- Author
-
Boydell, Emma, Marinari, Eliana, Migliorini, Denis, Dietrich, Pierre-Yves, Patrikidou, Anna, and Dutoit, Valérie
- Subjects
- *
PEPTIDES , *BEVACIZUMAB , *IMMUNOMODULATORS , *GLIOMAS , *IMMUNOTHERAPY , *RESEARCH , *STATISTICS , *SURVIVAL , *DATA analysis , *CANCER vaccines , *TREATMENT effectiveness , *VACCINES , *THERAPEUTICS - Abstract
Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in preclinical studies of glioma and in other tumour entities. Here, we conducted a post-hoc exploratory study to evaluate the effect of the IMA950/poly-ICLC peptide vaccine on subsequent BEV administration in high-grade glioma patients. 16 IMA950-vaccinated and 40 non-vaccinated patients were included. At initial diagnosis, patients benefited from surgery and chemoradiation. At first or subsequent recurrence, patients received 10mg/kg of BEV every 2–3 weeks. Primary endpoints were overall survival (OS) and progression-free survival (PFS) from BEV initiation. IMA950-vaccinated patients did not show improved response to BEV as compared to non-vaccinated patients: there was no difference in median PFS (2.6 vs. 4.2 months for vaccinated and control patients, respectively, p = 0.50) nor in median OS (7.8 vs. 10.0 months for vaccinated and control patients, respectively, p = 0.69). In conclusion, potential synergy of BEV and therapeutic vaccines, when administered sequentially, has yet to be established in the clinical setting of GBM recurrence. Potential synergy of concomitant administration should be tested in future trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. From Focused Ultrasound Tumor Ablation to Brain Blood Barrier Opening for High Grade Glioma: A Systematic Review.
- Author
-
Paun, Luca, Moiraghi, Alessandro, Jannelli, Gianpaolo, Nouri, Aria, DiMeco, Francesco, Pallud, Johan, Meling, Torstein R., Momjian, Shahan, Schaller, Karl, Prada, Francesco, and Migliorini, Denis
- Subjects
- *
DRUG delivery systems , *ULTRASONIC imaging , *BLOOD-brain barrier , *SYSTEMATIC reviews , *CANCER chemotherapy , *GLIOMAS , *POSTOPERATIVE care , *SURGICAL complications , *TREATMENT effectiveness , *ABLATION techniques , *EVALUATION - Abstract
Simple Summary: High-grade glioma (HGG) is a burdening oncological pathology for which maximum safe resection followed by combined chemoradiation therapy is still the gold standard. Despite these treatments the overall survival is less than 2 years. Alternative strategies are currently being investigated, including Focused Ultrasound (FUS). Given its non-invasiveness and promising pre-clinical results for tumor ablation, brain-blood barrier (BBB) opening and drug delivery, FUS is poised to achieve a therapeutic role in HGG treatment. This systematic review aims to identify the different modalities of how FUS can be used, how it impacts on survival in the clinic, based on the existing evidence. FUS-mediated tumor ablation still needs further investigation due to its controversial effects and complications. FUS-mediated BBB opening is showing positive results with low complication rate, as such potentially a gamechanger in future oncological treatments. Ongoing trials will clarify FUS impact on HGG patients. Background: Focused Ultrasound (FUS) is gaining a therapeutic role in neuro-oncology considering its novelty and non-invasiveness. Multiple pre-clinical studies show the efficacy of FUS mediated ablation and Blood-Brain Barrier (BBB) opening in high-grade glioma (HGG), but there is still poor evidence in humans, mainly aimed towards assessing FUS safety. Methods: With this systematic review our aim is, firstly, to summarize how FUS is proposed for human HGG treatment. Secondly, we focus on future perspectives and new therapeutic options. Using PRISMA 2020 guidelines, we reviewed case series and trials with description of patient characteristics, pre- and post-operative treatments and FUS outcomes. We considered nine case series (five about tumor ablation and four about BBB opening) with FUS-treated HGG patients between 1991 and 2021. Results: Sixty-eight patients were considered in total, mostly males (67.6%), with a mean age of 50.5 ± 15.3 years old. Major complication rates were found in the tumor ablation group (26.1%). FUS has been rarely applied for direct tumoral ablation in human HGG patients with controversial results, but at the best of current studies, FUS-mediated BBB opening is showing good results with very low complication rates, paving the way for a new reliable technique to improve local chemotherapy delivery and antitumoral immune response. Conclusions: FUS can become a complementary technique to surgical resection and standard radiochemotherapy in recurrent HGG. Ongoing trials could provide in the near future more data on FUS-mediated BBB opening impact on progression-free survival, overall survival and potential drug-delivery capacities. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.